Role of MRI in the Evaluation of Hepatic Metastases of Colorectal Cancer

Single-center Ambispective Observational Study on the Role of Magnetic Resonance Imaging (MRI) in the Evaluation of Patient Affected by Hepatic Metastases of Carcinoma of the

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05950503

Acronym

RMN-CRC

Enrollment

100

Registered

2023-07-18

Start date

2023-07-10

Completion date

2027-06-07

Last updated

2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

This study wants to evaluate the use of MRI in the managemente of mCRC with liver only metastases.

Detailed description

This study wants to evaluate the use of MRI in the managemente of mCRC with liver only metastases.

Interventions

RADIATIONHepatic MRI

The patients will undergo hepatic MRI in pre-established timepoints

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Inclusion criteria

* Age \> 18 years; * Histological diagnosis of colorectal cancer; * Presence of liver metastases in the staging exams (chest-abdomen CT with contrast medium or PET-CT with 18-FDG); * At least one measurable liver lesion according to RECIST 1.1 criteria; * Adequate organ and marrow function.

Exclusion criteria

* Age \< 18 years; * Inability to undergo MRI; * Major contraindications to liver surgery; * No written informed consent.

Design outcomes

Primary

Measure	Time frame	Description
Surgery conversion rates	3 years	Negative conversion rate is: patients initially considered operable and subsequently not considered suitable for surgery compared to the total number of patients enrolled. Positive conversion rate is: patients initially deemed ineligible for surgery and subsequently operated, compared to the total number of patients enrolled.

Secondary

Measure	Time frame	Description
Overall survival	3 years	Time from enrollment to death

Countries

Italy

Contacts

Primary ContactLisa Salvatore, MD, PhD

lisa.salvatore@policlinicogemelli.it0630156318

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026